DRDO Invites Applications From Indian Pharma Firms For Bulk Production Of Covid Drug 2-DG

COVID-19 India: 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID-19 patients.

The Defence Research and Development Organisation or DRDO, which developed 2-Deoxy-D-Glucose (2-DG), a drug used for treatment of COVID-19 patients, has called for Expression of Interest to transfer the technology to Indian pharmaceutical industries for production. 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID-19 patients.